Key Highlights The peer-reviewed study, published in Pharmaceutics (MDPI), describes the non-clinical safety pharmacology, toxicokinetics and pharmacodynamics of VMX-C001 in...
Adopted USAN: Reltodecacog alfa has been adopted by the United States Adopted Names (USAN) Council as the non-proprietary name for...
Key Highlights The peer-reviewed study, published in Pharmaceutics (MDPI), describes the non-clinical safety pharmacology, toxicokinetics and pharmacodynamics of VMX-C001 in...
Adopted USAN: Reltodecacog alfa has been adopted by the United States Adopted Names (USAN) Council as the non-proprietary name for...
Nominated for the 2026 Prix Galien USA “Best Startup” Award, and shortlisted with partner CSL for “Deal of the Year”...
First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients taking...
Key Highlights The collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for...
Episode of The BioHub Podcast featuring our Chief Operating Officer Martijn Negen. In Q4 2025, VarmX signed a strategic collaboration...
VarmX and Rentschler Biopharma expand collaboration from early development to late‑stage and commercial manufacturing of VMX-C001 VMX‑C001 builds on strong...
Poster presentation highlights Phase 1 data showing VMX-C001 has no effect on the anticoagulant function of heparin in healthy subjects...
Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling...